Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP)

Sector: Healthcare Industry: Biotechnology CIK: 0001759186
Market Cap 31.41 Mn
P/B 3.03
P/E -2.78
P/S 62.69
ROIC (Qtr) -146.26
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 279,865.00
Debt/Equity (Qtr) 0.03
Add ratio to table...

About

Coeptis Therapeutics Holdings, Inc. (COEP), a company operating in the biotechnology industry, is dedicated to the development of novel therapies for various diseases, including oncology, respiratory viral infections, and autoimmune diseases. Its primary business activities revolve around researching, developing, and commercializing innovative therapeutic solutions. Coeptis Therapeutics Holdings, Inc. conducts its operations primarily in the United States, although its partnerships and collaborations span across various regions. The company's revenue...

Read more

Investment thesis

Bull case

  • Healthy cash reserves of 4.91M provide 37.80x coverage of short-term debt 129865, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 13.78M provides 49.22x coverage of total debt 279865, indicating robust asset backing and low credit risk.
  • Long-term investments of 6.94M provide solid 46.27x coverage of long-term debt 150000, indicating strategic financial planning.
  • Cash reserves of 4.91M provide ample 49.08x coverage of acquisition spending 100000, enabling strategic growth opportunities.
  • Robust tangible asset base of 13.78M provides 4.19x coverage of working capital 3.29M, indicating strong operational backing.

Bear case

  • Operating cash flow of (8.35M) barely covers its investment activities of 100000, with a coverage ratio of -83.52, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Investment activities of 100000 provide weak support for R&D spending of 1.31M, which is 0.08x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (8.35M) shows concerning coverage of stock compensation expenses of 1.30M, with a -6.42 ratio indicating potential earnings quality issues.
  • Operating earnings of (11M) show weak coverage of depreciation charges of 1.18M, with a -9.35 ratio indicating high capital intensity and potential reinvestment needs.
  • Free cash flow of (8.35M) represents just -11.80x of debt issuance 707781, suggesting concerning reliance on leverage rather than internal cash generation for growth.

Peer comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,204.25 Bn -1,306.67 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 486.51 Bn 7,097.20 97.84 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 122.05 Bn 30.87 10.17 1.85 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 83.00 Bn 18.42 5.79 2.71 Bn
5 ARGX Argenx Se 50.78 Bn 33.71 26,480.10 -
6 ALNY Alnylam Pharmaceuticals, Inc. 43.66 Bn 139.17 11.76 2.97 Bn
7 BNTC Benitec Biopharma Inc. 43.61 Bn -941.82 0.00 0.00 Bn
8 INSM INSMED Inc 28.88 Bn -24.40 64.61 0.74 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 2.17 11.06
EV to Cash from Ops. EV/CFO -3.68 26.32
EV to Debt EV to Debt 109.84 762.61
EV to EBIT EV/EBIT -2.79 -13.49
EV to EBITDA EV/EBITDA -2.55 8.61
EV to Free Cash Flow [EV/FCF] EV/FCF -3.68 25.66
EV to Market Cap EV to Market Cap 0.98 203.37
EV to Revenue EV/Rev 61.36 156.31
Price to Book Value [P/B] P/B 3.03 20.59
Price to Earnings [P/E] P/E -2.78 -0.88
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 -12.64
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.17
Dividend per Basic Share Div per Share (Qtr) 0.00 0.01
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.14
Interest Coverage Int. cover (Qtr) -39.21 956.66
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex Growth (1y) % 0.00 7.87
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 331.53 753.48
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -184.13 -57.63
EBITDA Growth (1y) % EBITDA 1y % (Qtr) -17.76 8.83
EBIT Growth (1y) % EBIT 1y % (Qtr) -184.13 -67.21
EBT Growth (1y) % EBT 1y % (Qtr) -188.52 -23.74
EPS Growth (1y) % EPS 1y % (Qtr) 22.48 -7.02
FCF Growth (1y) % FCF 1y % (Qtr) -20.92 -40.48
Gross Profit Growth (1y) % Gross Profit Growth (1y) % 0.00 264.51
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.04 0.14
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.00
Cash Ratio Cash Ratio (Qtr) 1.81 3.92
Current Ratio Curr Ratio (Qtr) 2.21 7.33
Debt to Equity Ratio Debt/Equity (Qtr) 0.03 0.48
Interest Cover Ratio Int Coverage (Qtr) -39.21 956.66
Times Interest Earned Times Interest Earned (Qtr) -39.21 956.66
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) -1,960.60 -17,888.70
EBIT Margin % EBIT Margin % (Qtr) -2,195.46 -18,246.34
EBT Margin % EBT Margin % (Qtr) -2,251.45 -19,108.08
Gross Margin % Gross Margin % (Qtr) 73.00 -10.30
Net Profit Margin % Net Margin % (Qtr) -2,251.50 -19,056.96